Sanofi-A Ventis Deutschland Gmbh

Sanofi

Other

Sanofi-Aventis

Aventis Pharma S.a.

Aventis Pharmaceuticals Inc.

Selectide Corporation

Martin Smrcina

Marcel Patek

Siegfried Stengelin

Matthias Gossel

Thomas Klabunde

Pavel Safar

James Spoonamore

Stefanie Flohr

Peter Strop

David Squire Thorpe

Gary A Flynn

Kenneth J Bordeau

Gregory H Merriman

Brian K Whiteley

Aleksandra Weichsel

Carolina Lanter

Kirsten Bjergarde

Joseph T Klein

Stephen A Baum

Zhaoxia Yang

Safar Pavel

Eric Wegrzyniak

Hartmut Strobel

Kurt Ritter

Michel Tabart

Brian S Freed

Baptiste Ronan

Eric Bacque

Paulus Wohlfart

Sandor Batori

Fabrice Viviani

Henning Steinhagen

Vincent Leroy

Imre Bata

Anil Nair

Petra Lennig

Frantisek Turecek

Terry N Olney

Catherine Souaille

Tieu-Binh Le

Brian L Pedgrift

Péter Buzder-Lantos

Adi A Scheidemann

Yann Foricher

Petra Stahl

Mark Dodson

Veronika Bartane Bodor

Zsuzsanna Tomoskozi

Gerard Charles Rosse

Gyorgy Ferenczy

Stanly John

Attila Vasas

Frank J Schumacher, Iv

Gabor Szeleczky

Antonio Daniel Ramos

William Shelly Wire

Jianhong Zhao

Viviane Van Dorsselaer

Fabienne Weber

Dagmar Dasha Cabel

Martha Ackerman-Berrier

Jochen Huber

Bernard Pirard

Linli Wei

Thomas Joseph Caulfield

Andreas Weichert

Jennifer Williford Clemens

Robert S Francis

Daniel Schirlin

David S Thorpe

Dagmar D Cabel

Aleksandra Sanofi-Aventis Weichsel

The invention relates to derivatives of pyrazole 3,5-carboxylates, of general formula (I): in which R, R, R, R, R, X, Y, V, W and n are as defined herein. The invention also relates to salts of these compounds as well as hydrates or of solvates, enantiomers, diastereoisomers and mixtures thereof. Also disclosed are the methods of preparation and application in therapeutics of compounds of formula (I).

Derivatives of pyrazole 3,5-carboxylates, their preparation and their application in therapeutics

The present invention relates to compounds of formula 1 that are useful for the preventive or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to novel intermediates used in the preparation of said compounds.

Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists

The present invention relates to novel compounds of the formula Ia: in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity, and are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.

Substituted benzoylamino-indan-2-carboxylic acids and related compounds

This invention is directed to a 3-(amido or sulphamido)-4-(4-substituted-azinyl)benzamide or benzsulphonamide compound as defined herein. The 3-(amido or sulphamido)-(4-substituted-azinyl)benzamide or benzsulphonamide compound is useful as a inhibitor of the chemokine receptor CxCR3, and for preventing or treating a CxCR3 chemokine receptor mediated disease or condition related thereto in a patient in need of such.

Inhibitors of the chemokine receptor CxCR3

The disclosure relates to compounds of formula (I): which modulate the activity of proteins, particularly kinases, and to compositions containing the same, and to the use thereof as medicaments, in particular as anticancer agents.

7-substituted aza-indazoles, compositions containing same, production method and use thereof

The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicaments.

Hexahydro-pyrazino[1,2-A]pyrimidine-4,7-dione derivatives substituted with amino acids

The invention relates to 6-amido substituted pyrazolopyridine derivatives of the formula (I) useful as inhibitors of beta-adrenergic receptor kinase 1 (&#x3b2;ARK-1), compositions containing such compounds and their use for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.

Pyrazolopyridine derivatives as inhibitors of &#x3b2;-Adrenergic receptor kinase 1

The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.

Substituted hexahydropyrazino [1,2-A] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments

Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for the preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.

Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments

Substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.

Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments

The present invention relates to triaza- and tetraaza-anthracenedione derivatives of the formula I, wherein A, B and Rto Rare as defined herein. The compounds of formula I are valuable pharmacologically active compounds. They are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency. They upregulate the expression of the enzyme endothelial nitric oxide (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals

An apparatus and method for synthesizing a combinatorial library comprising a plurality of chemical compounds such that the chemical composition of each compound is easily tracked. The library compounds are synthesized on solid-phase supports, which are spatially arranged in frames during synthesis according to a predetermined protocol, such that each solid-phase support passes through a series of unique spatial 2D or 3D addresses by which the chemical composition of each compound may be determined at any point during synthesis. Solid-phase supports include hollow tubular-shaped lanterns and gears.

Apparatus and method for synthesizing combinatorial libraries

The present invention provides an instrument and methods for the preparative separation of components of mixtures using mass spectrometric methods. Nondestructive ionization methods are employed to generate ionized components of a mixture, the ionized components are spatially separated by mass and the mass-separated ion components are trapped. The ion source and mass spectrometric techniques employed allow the generation of large ion currents of ion components, on the order of nanoamps, which facilitate rapid accumulation of nanomole quantities of mass-separated components in relatively short times (minutes to hours).

Preparative separation of mixtures by mass spectrometry

Apparatus and method for synthesizing combinational libraries

Growing community of inventors

Tucson, AZ, United States of America

Martin Smrcina